Add Company
Join Now

Neuvivo Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Neuvivo's estimated annual revenue is currently $697.5k per year.(i)
  • Neuvivo's estimated revenue per employee is $77,500

Employee Data

  • Neuvivo has 9 Employees.(i)
  • Neuvivo grew their employee count by 0% last year.

Neuvivo's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Program ManagementReveal Email/Phone
3
Head CommunicationsReveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Neuvivo?

Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.

keywords:N/A

N/A

Total Funding

9

Number of Employees

$697.5k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M9N/AN/A
#2
$0.7M9N/AN/A
#3
$0.7M9N/AN/A
#4
$0.7M9N/AN/A
#5
$0.7M9N/AN/A